Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients"

Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients | AIDS Research and Therapy BioMed Central Open Access Formulation preference tolerability and quality of life assessment following a switch from lopinavir ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients Ighovwerha Ofotokun 1 Susan K Chuck2 Brian Schmotzer3 and Kelly L O Neil2 Address Department of Medicine Division of Infectious Diseases Emory University School of Medicine 49 Jesse Hill Jr. Drive Atlanta GA 30303 USA 2Abbott Laboratories 200 Abbott Park Rd Abbott Park IL 60064 USA and 3Department of Biostatistics Emory University Rollins School of Public Health 1518 Clifton Road Atlanta Georgia 30322 USA Email Ighovwerha Ofotokun - iofotok@emory.edu Susan K Chuck - Susan.chuck@abbott.com Brian Schmotzer - bschmot@sph.emory.edu Kelly L O Neil - kelly.oneil@abbott.com Corresponding author Published 22 December 2009 Received 9 September 2009 AIDS Research and Therapy 2009 6 29 doi 10.1186 1742-6405-6-29 Accepted 22 December 2009 This article is available from http www.aidsrestherapy.cOm content 6 1 29 2009 Ofotokun et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Lopinavir ritonavir LPV r tablet compared to the soft gel capsule SGC formulation has no oleic acid or sorbitol has no refrigeration or food-restriction requirements and has less pharmacokinetic variability. We compared the tolerability quality of life QoL and formulation preference after switching from LPV r SGC to the tablet formulation. Methods In a prospective single-arm cohort study-design 74 human immunodeficiency virus HIV infected subjects stable on LPV r-based therapy were enrolled prior to n 25 or 8 weeks n 49 after switching from SGC to tablet. Baseline data included clinical laboratory tests .